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Background: Gliomas account for more than 60 % of all primary central nervous system neoplasms. Low-grade
gliomas display a tendency to progress to more malignant phenotypes and the most frequent and malignant gliomas
are glioblastomas (GBM). Another type of glioma, oligodendroglioma originates from oligodendrocytes and glial
precursor cells and represents 2–5 % of gliomas. The discrimination between these two types of glioma is actually
controversial, thus, a molecular distinction is necessary for better diagnosis.
Methods: iTRAQ-based quantitative proteomic analysis was performed on non-neoplastic brain tissue, on astrocytoma
grade II, glioblastoma with short and long survival and oligodendrogliomas.
Results: We found that expression of nucleophosmin (NPM1), glucose regulated protein 78 kDa (GRP78), nucleolin
(NCL) and heat shock protein 90 kDa (HSP90B1) were increased, Raf kinase inhibitor protein (RKIP/PEBP1) was
decreased in glioblastoma and they were associated with a network related to tumor progression. Expression
level of heat shock protein 27 (HSPB1/HSP27) discriminated glioblastoma presenting short (6 ± 4 months, n = 4)
and long survival (43 ± 15 months, n = 4) (p = 0.00045). Expression level of RNA binding protein nova 1 (NOVA1)
differentiated low-grade oligodendroglioma and astrocytoma grade II (p = 0.0082). Validation were done by
Western blot, qRT-PCR and immunohistochemistry in a larger casuistry.
Conclusion: Taken together, our quantitative proteomic analysis detected the molecular triad, NPM1, GRP78
and RKIP participating together with NCL and HSP27/HSPB1 in a network related to tumor progression.
Additionally, two new important targets were uncovered: NOVA1 useful for diagnostic refinement differentiating
astrocytoma from oligodendroglioma, and HSPB1/HSP27, as a predictive factor of poor prognosis for GBM.
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Gliomas are the most frequent primary tumors of the
central nervous system, accounting for more than 60 %
of all brain tumors, and comprise of astrocytomas, oligo-
dendrogliomas, oligoastrocytomas, and ependinomas [1].
Among them, glioblastoma (GBM-grade IV astrocytoma)
is the most malignant glioma and despite continuous ef-
forts, the median survival still remains around 15 months
after the establishment of diagnosis and the standard
care with radiation therapy and chemotherapy with
temozolamide [2]. The main study design concerning
GBM has aimed to uncover specific drugable targets in
signaling pathways with impact in the tumorigenic
process and in the extension of overall survival time [3].
In this context, we have recently described two proteins,
nucleophosmin (NPM1) and RKIP, involved in RAS/
RAF/MAPK and PI3K/AKT/mTOR pathways [4]. We
have also shown that NPM1 knockdown sensitized GBM
cell lines to cell death after treatment with temozolamide
[5]. Moreover, when NPM1 expression was silenced,
expression of GRP78, a member of the heat shock protein
70 involved in protein unfold response, was concomitantly
decreased. GRP78 expression was high in GBM, and
correlated to cell migration [6]. In the present study we
have compared the protein expression profiles of GBM
cases presenting short and long survival time, and astrocy-
toma and oligodendroglioma of different grades of malig-
nancy to further understand the mechanisms of tumor
aggressiveness.
Another strategy to understand the rules governing
the aggressive behavior of gliomas is to compare astrocy-
toma to oligodendroglioma, where the latter type of
glioma presents a less aggressive clinical evolution. Five
and 10 years survival rates for oligodendroglioma are 78
and 51 %, respectively, whereas among astrocytoma they
are 65 and 31 %, respectively [7, 8]. This survival rate
difference is due partially to a better response of oligo-
dendroglioma to chemotherapy, including temozolomide
or PCV- procarbazin, 1-(2-cloroethyl)-3-cyclohexil-L-
nitrosurea and vincristin [9–14] and to radiation therapy
[15, 16]. Therefore, further analysis of differential pro-
tein profiles of these glioma types may help to: 1) refine
the histopathologic diagnosis, currently based mainly in
morphologic characteristics, with large interobserver
variability [17, 18], and 2) detect molecular targets that
may explain the difference of clinical outcome between
low grade astrocytoma and oligodendroglioma.
In this study, we took advantage of isobaric tags for
relative and absolute quantification (iTRAQ-8plex) to
investigate the proteome related to tumor progression
and aggressiveness comparing a set of astrocytoma grade
II to oligodendroglioma grade II, and a set of GBM cases
presenting short survival (6 ± 4 months, n = 4) to GBM
cases with long survival (43 ± 15 months, n = 4). Wehave succeeded in uncovering differential protein pro-
files between these compared sets, highlighting two tar-
gets, HSPB1/HSP27 and NOVA1, related to tumor
progression and differentiation. Both selected targets
were further validated at mRNA expression levels by
quantitative PCR, and protein expression and intracellu-
lar localization by immunohistochemistry in an inde-
pendent casuistry of human glioma samples.
Methods
Tissue processing
Tissue samples from tumors were collected during
surgery and stored at −80 °C. Tissue samples were micro-
dissected in order to remove areas of necrosis, cellular
debris and any non-neoplastic tissue prior to protein,
DNA and RNA extraction. The tumor area of interest was
concomitantly collected for pathological diagnosis and
grade stratification according to the latest WHO classifica-
tion of CNS tumors by two independent pathologists. The
tumors were graded as AST II astrocytoma grade II (AST
II), glioblastomas (GBM) and oligodendrogliomas grade II
(OLI II) and oligodendrogliomas grade III (OLI III). GBMs
were divided in two subgroups based on patients’ overall
survival time after diagnosis as GBM of short survival
(GBM-SS, 6 ± 4 months, n = 4) and long survival (GBM-
LS, 43 ± 15 months, n = 4). Non-neoplastic brain tissues
(NN, mean age at surgery, 29 ± 7 years, n = 4) were
obtained from individuals submitted to temporal lobe
resection for epilepsy surgery and examined by a patholo-
gist who confirmed the abundance of astrocytic cells in
the resected tissue. Four samples for each group were
pooled and analysed by the proteomic approach (ASTII
mean age at diagnosis, 33 ± 7 years; GBM-SS 48 ± 23 years;
GBM-LS 48 ± 18 years; OLI II 42 ± 16 years and OLI III
48 ± 15 years). An independent casuistry comprised of 22
(NN), 23 (AST I), 26 (AST II), 18 (AST III), 83 (AST IV
or GBM), 25 (OLI II), and 26 (OLI III) was analyzed at the
validation step by qRT-PCR for the selected targets. All
samples were collected during surgical procedures by the
Neurosurgery Group of the Department of Neurology at
the Hospital das Clinicas of School of Medicine of São
Paulo, University of Sao Paulo, Brazil from 2000 to 2008
and the follow-up of cases are being carried out to date.
This study was approved by the Brazilian National Bioeth-
ics Commission (CONEP), and by the Ethics Committee
of the Medical School of Ribeirao Preto and School of
Medicine of São Paulo of the University of Sao Paulo.
Written consent was obtained from each patient authoriz-
ing the use of their tissues in the present investigation.
Tumor protein extraction
Tissue samples were mechanically homogenized in lysis
buffer containing 30 mM Tris-HCl pH 7.5, 150 mM
NaCl, 1 % Triton X-100, 10 % glycerol and a protease
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20,000 g for 30 min, the supernatants were precipitated
with 20 % trichloroacetic acid and washed three times
with cold acetone. Electrophoresis buffer (200 µL)
containing 10 mM Tris base, pH 9.0, 7 M urea, 2 M
thiourea, 65 mM DTT and 4 % CHAPS was added to
each pellet. Proteins pellets were then submitted to three
cycles of 5 min each in an ultrasound bath (UltraSonic
Clear 750, UNIQUE) centrifuged and supernatant were
kept for protein concentration determination.Sample preparation and iTRAQ labeling
Each protein extract of tumor and non-neoplastic tissue
were quantified by the method of Bradford [19]. Twenty
five μg of each patient sample was pooled to normalize
100 μg total protein for each category. Additional file 1:
Figure S1 describes a schematic experimental approach.
Pooled samples were mixed with 6× volume of cold
acetone (−20 °C) and incubated for 60 min at −20 °C.
The proteins pellets were reconstituted according to
manufacturer’s protocol (Applied Biosystems, Framing-
ham, MA, USA). Briefly, proteins pellets were re-
suspended into 20 μL of dissolution buffer (0.5 M
triethylammonium bicarbonate), 1 μL denaturant (2 %
SDS), and 2 μL reducing reagent (50 mM tris-(2-carbox-
yethyl) phosphine). Free cysteine was blocked by adding
1 μL of 200 mM methyl methanethiosulfonate in isopro-
propanol. Sequencing grade modified trypsin was from
Promega (Madison, WI) and was reconstituted with de-
ionized water at 1 μg/μL concentration. In each vial
10 μL of trypsin solution was added and incubated over-
night (18 h) at 37 °C. Reagents of 8plex iTRAQ were
allowed to reach room temperature and then reconsti-
tuted with 50 μL of isopropanol. Each label reagent was
mixed with the corresponding protein digest and incu-
bated at room temperature for 2 h. Samples were pooled
into a new vial and dried in SpeedVac (Savant Inc, New
York, NY). After reconstituted with 0.1 % formic acid
(FA), the digest was desalted on a Waters Oasis HLB
column and eluted with 60 % acetonitrile (ACN)/ 0.1 %
FA. Eluted peptide mixture was dried.Strong cation exchange fractionation (SCX)
The sample was reconstituted with 100 μL SCX buffer A
(10 mM KH2PO4, 20 % ACN, pH2.7) and separated on a
PolyLC Poly-sulfoethyl-A column (200x2.1 mm, 5 μm,
200 Å) with a linear 200 μL/min gradient of 0-70 %
buffer B (10 mM KH2PO4, 20 % ACN, 500 mM KCl,
pH2.7) in 45 min on an Agilent 1200 LC device with
Chemstation B.02.01 control software. Fractions were
collected each minute and eventually pooled into 20
fractions. The fractions were desalted, eluted, and dried
as described above using Waters Oasis HLB column.Mass spectrometry
The samples were reconstituted with 0.1 % formic acid.
Liquid chromatography was performed on an Eksigent
nanoLC-Ultra 1D plus system (Dublin, CA). Peptide
digest was first loaded on a Zorbax 300SB-C18 trap
(Agilent, Palo Alto, CA) at 6 μL/min for 5 min, then
separated on a PicoFrit analytical column (100 mm long,
ID 75 μm, tip ID 10 μm, packed with BetaBasic 5 μm
300 Å particles, New Objective, Woburn, MA) using a
40-min linear gradient of 5-35 % ACN in 0.1 % FA at a
flow rate of 250 nL/min. Mass analysis was carried out
on an LTQ Orbitrap Velos (Thermo Fisher Scientific,
San Jose, CA) with data-dependent analysis mode, where
MS1 scanned full MS mass range from m/z 300 to 2000
at 30,000 mass resolution and six HCD MS2 scans were
sequentially carried out at resolution of 7500 with 45 %
collision energy, both in the Orbitrap.
Database search and quantitative data analysis
MS/MS spectra from 20 fractions were searched against
the Swiss Prot (Swiss Institute of Bioinformatics) data-
base, taxonomy Homo sapiens (human) using Mascot
software (Matrix Science, London, UK; version 2.3), with
precursor mass tolerance at 20 ppm, fragment ion mass
tolerance at 0.05 Da, trypsin enzyme with 2 misclea-
vages, methyl methanethiosulfonate of cysteine and
iTRAQ 8plex of lysine and the n-terminus as fixed mod-
ifications, and deamidation of asparagine and glutamine,
oxidation of methionine and iTRAQ 8plex of tyrosine as
variable modifications. The resulting data file was loaded
into Scaffold Q+ (version Scaffold 4.3.0, Proteome Soft-
ware Inc., Portland, OR) to filter and quantitate peptides
and proteins. Peptide identifications were accepted at
80.0 % or higher probability as specified by the Peptide
Prophet algorithm [20] and a false discovery rate (FDR)
of less than 1 %. Protein identifications were accepted at
95.0 % or higher probability and contained at least 2
identified peptides with FDR less than 1 %. Protein prob-
abilities were assigned by the Protein Prophet algorithm
[21]. Proteins that contained similar peptides and could
not be differentiated based on MS/MS analysis alone
were grouped to satisfy the principles of parsimony. Pep-
tides were quantified as the centroid reporter ion peak
intensity, with minimum of 5 % of the highest peak in
the spectrum. Intra-sample channels were normalized
based on the median ratio for each channel across all
proteins. Isobaric tag sample was normalized by compar-
ing the median protein ratios for the reference channel.
Quantitative protein values were derived from only
uniquely assigned peptides. Protein quantitative ratios
were calculated as the median of all peptide ratios.
Standard deviations were calculated as the interquartile
range around the median. Quantitative ratios were log2
normalized for final quantitative testing.
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The samples were diluted in NuPAGE SDS Sample
buffer (Invitrogen NP0007) and the SDS-PAGE was
performed using NuPAGE Novex Bis-Tris Mini Gels
4–12 %. SDS-PAGE gels were electrobloted in iBlot Device
and the membranes were incubated with primary
antibodies HSPB1/HSP27 and HSP90B1(GRP94) from
Cell Signaling Technology; NPM and RKIP from
Zymed-Invitrogen; NCL and β-actin from Santa Cruz
Biotechnology; NOVA-1 from Sigma-Aldrich. The
same source of antibodies HSPB1 and NOVA1 were
used for immunohistochemistry.
RNA extraction and cDNA synthesis
Total RNA was extracted from each tissue using the
RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA
quantification and purification was determined by meas-
uring absorbance at 260 and 280 nm. A260/A280 ratios
in the 1.8–2.0 range were considered to indicate a satis-
factory level of purity. Denaturing agarose gel electro-
phoresis was used to assess the quality of the samples.
cDNA synthesis was performed by reverse transcription
of 1 μg total RNA previously treated with one unit of
DNase I (FPLC-pure, GE Healthcare, Piscataway, NJ,)
using random and oligo(dT) primers, RNase inhibitor,
and SuperScript III (Life Technologies) according to the
manufacturer’s recommendations.
Quantitative real-time PCR (qRT-PCR)
For qRT-PCR, quantitative data were normalized relative
to the internal housekeeping control genes hypoxanthine
phosphoribosyltransferase 1 (HPRT), beta-glucuronidase
(GUSB), and TATA-box binding protein (TBP) [22]. The
geometric mean of the housekeeping genes was used for
the analysis of relative expression of tissue samples. Pri-
mer sequences were as follows (5′– 3′): HSPB1 F:
GGACGAGCTGACGGTCAAGA, HSPB1 R: CGGGA
GATGTAGCCATGCT, NOVA1 F: GGAGCCACCATC
AAGCTGTCTA, NOVA1 R: TCAGTGCTTCAACCGT
TCCCT, HPRT F: TGAGGATTTGGAAAGGGTGT,
HPRT R: GAGCACACAGAGGGCTACAA, GUSB F: A
AAATACGTGGTTGGAGAGCTCATT, GUSB R: CCG
AGTGAAGATCCCCTTTTTA, TBP F: AGGATAAGA
GAGCCACGAACCA, and TBP R: CTTGCTGCCAGT
CTGGACTGT synthesized by IDT. Sybr Green I ampli-
fication mixtures (12 μL) contained 3 μL cDNA, 6 μL
2 × Power Sybr Green I Master Mix (Applied Biosys-
tems, Foster City, CA), and forward and reverse
primers at final concentrations of 200–400 nM. Reac-
tions were run on an ABI 7500 Real-Time PCR Sys-
tem (Applied Biosystems). The cycling conditions
were: incubation at 50 °C for 2 min to activate UNG,
initial denaturation at 95 °C for 10 min, and 40 cycles
of 15 s each at 95 °C and at 60 °C for 1 min. DNAmelting curve analysis showed a single peak for all
genes. The 2−ΔΔCT equation was applied to calculate
the relative expression [23]. For the relative expres-
sion analysis of GBM cases, the mean of control non-
neoplastic brain samples was used as calibrator.
Immunohistochemistry
For immunohistochemical detection of HSPB1 and
NOVA1, tissue sections were routinely processed and
subjected to antigen retrieval. Briefly, slides were
immersed in 10 mM citrate buffer, pH 6.0 and incubated
at 122 °C for 3 min using an electric pressure cooker
(BioCare Medical Walnut Creek, CA). Specimens were
then blocked and further incubated with a mouse mono-
clonal antibody raised against human HSPB1 and
NOVA1 at a final dilution of 1:100 at 16-20 °C for 16 h.
The reaction was developed using a Novolink commercial
kit (Novocastra, New Castle, UK) at room temperature
using diaminobenzidine, and Harris hematoxylin for
nuclear staining. All prepared slides were independently
analyzed by two observers, and the positive reaction was
quantitated for HSPB1 and NOVA1 as the percentage of
positive cytoplasm/nuclei cells: zero (0), when no positiv-
ity was detected; 1, when up to 25 % of positive cells were
present; 2, for 26-50 % of positive cells; 3, for 51-75 % of
positive cells, and 4, for over 76 % of positive cells.
Statistical analysis
The statistical analysis of HSBP1 and NOVA1 expression
by qRT-PCR in astrocytomas, oligodendrogliomas and
non-neoplastic tissues was performed by Kruskal-Wallis
and Mann-Whitney tests as well as the proteomic profil-
ing through statistical package included in Scaffold
v.4.3.0 software, blocked t-test and ANOVA for categor-
ies (p-value, ASTRO, OLI or ASTRO/OLI) (Proteome
Software, Inc, Portland, Oregon). Discrimination of
variables was calculated by the receiver operator charac-
teristic (ROC) curve utilizing area under curve and
asymptotic significance. The continuous variables were
categorized through a curve using ROC the value with
the best sensitivity and specificity. Differences in gene
and protein expressions were considered to be statisti-
cally significant at p < 0.05.
Results
Identification of proteins differentially expressed in
gliomas using isobaric tags for relative and absolute
quantification (iTRAQ)
Proteomic analysis using iTRAQ isobaric tags was per-
formed using pool of samples from astrocytoma grade II
(AST II), glioblastoma (GBM) sub-grouped into cases pre-
senting short and long survival after diagnosis (GBM-SS,
6 ± 4 months, n = 4 and GBM-LS43 ± 15 months, n = 4,
respectively), oligodendroglioma grade II (OLI II) and
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selected and quantified in Scaffold software v.4.3.0 (Fig. 1
and Table 1). Proteins were differentially expressed when
compared to non-neoplastic tissue (NN) as the ratio was
above or below Log2 Fold Change (0.6 = 1.5-fold) and
statistically significant between categories. The results of
the following sets were compared: 1) AST II vs. GBMs,
and OLI II vs. OLI III to address protein involved in
tumor malignant progression; 2) GBM-SS vs. GBM-LS toFig. 1 Proteins differentially expressed in astrocytomas and oligodendrogli
proteins by log2 fold change for each of the selected proteins which are c
intensities appearing in the spectra included in NN category and that the s
the isobaric tag peak intensities within the reference label in respect to theaddress proteins involved in prognosis; 3) AST II vs. OLI
II to address proteins involved in the differentiation
between these two low grade gliomas with impact in
tumor aggressiveness. We were able to identify 1095 pro-
teins labeled with iTRAQ and using minimum of 2 pep-
tides per protein (Additional file 3: Table S1 - Protein
report and Additional file 4: Table S2 Peptide report),
which 268 presented difference of expression in at least
one group (Additional file 5: Table S3 Protein ratio). Theomas. Panels A to H in the figure represent the differentially expressed
alculated dividing all the peaks by the average of the isobaric tag peak
pread shown for the log2 fold change of NN illustrates the variation of
ir average
Table 1 Selected proteins from quantitative proteomic analysis of astrocytomas and oligodendriomas tumor samples (n = 4).
Proteins are expressed as log2 fold change in relation to non-neoplastic brain tissue (NN)


















EGFR Ref 0.2 1.5 2.2 0.3 0.6 20 13.2 0.0023 0.93 <0.0001
Nucleophosmin NPM1 Ref 0.2 1.1 1.1 0.8 1.3 14 32.3 0.0049 <0.0001 <0.0001
78 kDa glucose-regulated
protein
GRP78 (HSPA5) Ref 0.3 1.1 0.9 0.2 0.6 44 43.0 <0.0001 0.0008 0.037
Phosphatidylethanolamine-
binding protein 1
PEBP1 (RKIP) Ref -0.4 -1.0 -1.1 -0.6 -1.4 36 79.1 <0.0001 <0.0001 <0.0001
Heat shock protein beta-1 HSPB1 Ref 0.1 1.6 0.8 0.3 0.5 9 49.8 0.00045 0.89 0.28
RNA-binding protein Nova-1 NOVA1 Ref 0.1 0.9 2.2 0.8 1.3 3 7.8 0.120 0.011 0.0082
Endoplasmin (ENPL) HSP90B1 Ref 0.2 1.0 0.9 0.6 1.0 44 25.8 <0.0001 <0.0001 <0.0001
Nucleolin NCL Ref 0.2 1.3 1.1 1.0 1.9 27 25.1 <0.0001 <0.0001 <0.0001
Statistical test for ratio-based normalization of isobaric tags (Scaffold v.4.3.0) - The samples were grouped as follows:
aastrocytomas = NN, AST II, GBM-SS and GBM-LS
boligodendroglioma = NN, OLI II and OLI III
cstrocytoma and oligodendroglioma = NN, AST II and OLI II
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expressed were mainly involved with metabolic processes,
biological processes regulation and binding to proteins,
RNA and nucleotides.
Selection and validation of proteins involved in tumor
malignant progression
Proteins selected as having alteration of expression and
known to participate in the process of tumor progres-
sion are shown in Table 1 and Fig. 1. NPM1, RKIP/
PEBP1 and GRP78 expressions were significantly distinct
in GBMs and oligodendrogliomas compared to AST II and
NN (p < 0.0001, blocked t test), corroborating previous
data of our group [4–6]. Particularly, NPM1 expression
presented correlation with tumor malignant progression as
lower expressions were observed in non-neoplastic tissue,
AST II and OLI II compared to the expressions of GBM
and OLI III. Interestingly, phosphatidylethanolamine-
binding protein 1 (PEBP1), also known as raf kinaseFig. 2 Western blot validation of differentially expressed proteins in patien
patient sample used for quantitative proteomics was used for validation byprotein inhibitor (RKIP), was decreased in high grade gli-
omas in relation to the non-neoplastic tissue and lower
grade gliomas, as previously demonstrated by our group
[4]. These reproduced data related to NMP1, GRP78 and
RKIP demonstrated the consistency of the proteomics re-
sults herein presented by iTRAQ methodology. Also,
EGFR was highly expressed in GBM compared to AST II,
as expected, however, similar results were not observed for
OLI II and III (p = 0.930) (Fig. 1a). Selected proteins as
NPM1, RKIP, HSP90B1 and NCL were also differentially
expressed among the analyzed subgroups and these levels
of expression were validated by western blotting of pooled
samples (Fig. 2). GRP78 was previously validated elsewhere
[5, 6].
HSPB1 (HSP27) as a predictive factor between GBM cases
with short and long overall survival time
The most interesting differentially expressed protein was
heat shock protein beta-1 (HSPB1) (Fig. 1g, Table 1) thatt pools of astrocytomas and oligodendrogliomas. The same pool of
immunodetection. The assay was normalized to actin
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especially when compared to GBM-long survival (GBM-
LS) (p = 0.00045). This finding was also observed at the
HSPB1 mRNA expression level, where its expression
was significantly different among GBM patients who
presented less than 12 months of survival time com-
pared to those presenting more than 16 months survival
(p = 0.0287, Mann Whitney test). HSPB1 expressions
were still distinct when GBMs cases with less than
12 months and more than 24 months survivals were
compared (p = 0.0816, Mann Whitney test) (Fig. 3a andFig. 3 Validation of proteomic data of HSPB1 in glioma patient samples. a
time (<12 months) and long survival (>16 months). b Re-analysis of the qR
(<12 months) and long survival patients (>24 months). Data analyses were
and Mann Whitney statistical test. c Western blot of HSPB1 in individual ast
AST II = astrocytoma grade II, GBM-SS = glioblastoma short survival and GBM
HSPB1 in low-grade to high-grade gliomas. a Non neoplastic (NN); b Pilocy
astrocytoma (ASTIII), and e Glioblastoma (GBM) short survival (5 months), an
expression of HSPB1b). Statistical significance would be reached increasing
the number of observations of GBM cases presenting
overall survival time longer than 24 months, a very rare
condition. Additionally, a stepwise increase of HSPB1
mRNA expression was observed in parallel to the
increase in malignancy mainly in diffusely infiltrative
astrocytomas from grade II to IV (p <0.05 to p <0.0001,
Kruskal Wallis and Dunn's tests), and when these results
were plotted on ROC curves, an increasing value of the
area in parallel to the increment of the malignancy was
observed (Fig. 4a), strongly suggesting that HSPB1qRT-PCR of HSPB1 gene in GBM patient samples with short survival
T-PCR of HSPB1 gene in samples for a longer interval between short
normalized by the same set of housekeeping genes: HPRT, GUSB, TBP
rocytoma patient samples (n = 3 and 4); (NN = non-neoplastic tissue;
-LS = glioblastoma long survival. d Immunohistochemistry (IHC) of
tic astrocytoma (ASTI); c Diffuse astrocytoma (ASTII); d Anaplastic
d f GBM long survival (27 months). g graphical-plot of IHC relative
Fig. 4 a ROC curves comparing HSPB1 expression levels of NN group compared to each grade of malignant astrocytomas, grade II to IV. The
values of area, standard error under the nonparametric assumption, and asymptotic significance considering null hypothesis of true area - 0.5;
b Kaplan-Meier curves. Overall survival time of GBM cases presenting HSPB1 expression level > 23.28 (3 fold of cut off value determined by ROC
curve) (n = 29) compared to GBM cases presenting HSPB1 expression level < 23.28 (n = 48). Log rank = 0.007
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Moreover, when the overall survival times of GBM cases
presenting ±3 fold cut off value of HSPB1 expression level
calculated based on the ROC curve (3×7.76 = 23.28) were
compared to those presenting HSPB1 expression
level < 23.28, it resulted in a Kaplan-Meier curve with
log rank of 0.007 (Fig. 4b). This finding was inde-
pendent to the IDH1 mutation status [24], according to
multivariate proportional hazards analysis (Cox model),
where HSPB1 expression status (hyper and hypo
expression) presented hazard ratio (HR) of 1.86 with
95 % confidence interval (CI) ranging from 1.14 ± 3.03,
and p value of 0.012. On the other hand, IDH1 muta-
tion status (mutated IDH1 compared to wild type) pre-
sented HR = 1.35, 95 % CI = 0.64 ± 2.84, p = 0.43. Similar
analysis was not feasible to MGMT methylation sta-
tus, as such results were available for only 51 out of
83 GBM cases due to limitation of biological sample.
Nevertheless, we have previously reported no impact
of MGMT methylation status on the overall survival
time among GBM cases of this series (log rank,
Mantel-Cox = 0.204) [25]. HSPB1 protein expression
levels of GBM cases with short and long survival
were validated individually by western blot analysis,
which showed more intense immunostaining of pro-
tein in GBM cases with short survival, confirming the
possible usefulness of HSPB1 as predictive factor of
worse prognosis (Fig. 3c). HSPB1 protein expression
was further confirmed by immunohistochemistry in
astrocytoma samples, comprising pilocytic astrocy-
toma (grade I), low grade astrocytoma (grade II), ana-
plastic astrocytoma (grade III) and GBM (grade IV)
with short (5 months) and long survival (27 months),
and in non-neoplastic brain tissue (Fig. 3d). High
abundance of HSPB1 was detected in grade IV astro-
cytoma, particularly in GBM-SS (5 months, Fig. 3d(e))
with unequivocal contrast to the weak labeling of a
GBM-LS case (27 months, Fig. 3d(f )). Graph of im-
munochemistry of HSPB1 was demonstrated in
Fig. 3d(g), showing that GBM-SS is highly positive in
contrast to GBM-LS. These results of proteomics,
gene and protein expressions allow to elect HSPB1 as
a predictive factor of tumor aggressiveness in a re-
stricted set of GBM cases, and it may worth further
exploration as a potential therapeutic target for these
specific cases.
NOVA1 as a differentiation factor between Low grade
astrocytoma and oligodendroglioma
RNA binding protein nova 1 (NOVA1) presented an
interesting expression profile when low grade astrocyto-
mas and oligodendrogliomas grade II were compared
(Table 1, p = 0.0082). qRT-PCR for NOVA1 showed a sig-
nificant difference between OLI II and AST II (p < 0.0005,Mann Whitney test) (Fig. 5a). NOVA1 was validated by
western blot through the analysis of patients of grade II
astrocytoma and oligodendroglioma II and III individually.
The results showed heterogeneity in the immunodetection
of NOVA1 and at least one case, the protein was not
detected, from a total of 4 samples in OLI II (Fig. 5b).
However, NOVA1 immunohistochemistry was highly con-
cordant with NOVA1 at mRNA level and proteomic pro-
filing, showing a major concentration of this protein in
nuclei compartment (Fig. 5c). NOVA1 can be used as a
molecular marker to differentiate low-grade astrocytoma
from low-grade oligodendroglioma, and therefore, may be
helpful for the refinement of the diagnosis currently based
mainly on histopathological characteristics.
Network analysis of molecular triad NPM1, RKIP and
GRP78 using metacore
The network analysis of three molecules NPM1, RKIP
and GRP78 by MetaCore program allowed the addition
of two proteins in the context of systems biology, HSPB1
(HSP27) and nucleolin (NCL), interconnected to at least
three transcription factors, ESR1, STAT3 and SP1, and
downstream of EGFR receptor pathway, classically
known as modified in GBM (Fig. 6). The results of this
network analysis highlight the importance of several
proteins found in this work to be altered in the tumor
samples and will be discussed later in the next section.
Discussion
One of the most productive and direct way of obtaining
information about the development of diseases such as
cancer, especially brain cancer, is the combination of
genomic and proteomic strategies of tumor specimens
taken from patients. Each tumor sample provides new
markers of the disease and improves the knowledge
about the biology of tumors. One of most important
findings of our report is the detection of NOVA1 as
differentiation factor between low-grade astrocytoma
and oligodendroglioma. The clinical impact of such a
diagnostic refinement based on molecular marker is
relevant as astrocytoma presents more aggressive pro-
gression than oligodendroglioma, and accordingly a
diagnosis of an astrocytic tumor requires more aggres-
sive therapeutic strategies. NOVA1 is an alternative
splicing factor involved in the main mechanism of in-
creasing proteome diversity coded by a limited number
of genes. Together with other splicing factors, including
ESRP1 and 2, MBNL1, PTBP1, and RBFOX2, NOVA1
contributes to establishing a cell type–specific splicing
programs [26]. The role of altered expression of
NOVA1 in glioma is still unknown. In oligodendrogli-
omas, Xu et al. [27] have reported the expression of
multiple larger-sized transcripts for several genes
attributed to hnRNP A1, a component of the
Fig. 5 Validation of proteomic data of NOVA1 in low-grade astrocytoma and oligodendroglioma patient samples. a qRT-PCR of NOVA1 gene in
astrocytoma grade II (AST II) and oligodendroglioma (OLI II and OLI III). Data analyses were normalized by same set of housekeeping genes: HPRT, GUSB,
TBP and Mann Whitney statistical test. b Western blot of NOVA1 in individual astrocytoma and oligodendroglioma patient samples (n = 3 and 4);
c Immunohistochemistry (IHC) of NOVA1 in astrocytomas and oligodendrogliomas. a Non neoplastic (NN); b Pilocytic astrocytomas (AST I); c Diffuse
astrocytoma (AST II); d Anaplastic astrocytomas (AST III), and e Glioblastoma (GBM, 200×) f Glioblastoma (GBM, 400×); g Oligodendroglioma II and
h Oligodendroglioma III. i Graphical plot of IHC relative expression of NOVA1 distribution between nucleus and cytoplasm
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site leading to a preferential expression of larger-sized
transcripts. These authors have suggested that the ex-
pression of large transcript could be useful for distin-
guishing oligodendroglial from astroglial gliomas [27].
In the present study, NOVA1 expression profile has
proved to also differentiate oligodendroglioma from as-
trocytoma, and NOVA1 higher expression in oligo-
dendroglioma may contribute to the preferential
splicing program in this type of glioma.
In this work, we also detected and validated HSPB1
(HSP27) as a predictive factor for poor prognosis in
GBM. High expression of HSPB1 was demonstrated in
GBM cases with survival time shorter than 12 months.
HSPB1 is a multifunctional protein that is dependent of
oligomerization and phosphorylation status [28]. HSPB1/
HSP27 is a human small heat shock protein, a chaperone
that regulates fundamental cellular processes in normal
unstressed cells as well as in many cancer cells, including
breast, ovarian, endometrial cancers, osteosarcoma, and
leukemia [29]. HSPB1/HSP27 is constitutively expressed
at low levels in many cells and tissues, and its increased
expression level has been correlated to the enhancement
of cellular resistance, even in the presence of DNAdamage due to UV radiation. Recently, the switch between
apoptosis and survival, modulated by Akt stability, has
been attributed to HSPB1/HSP27 in adenocarcinoma cells
[30]. Interestingly, a network analysis by MetaCore™ has
demonstrated that three targets, NPM1, GRP78 and RKIP,
previously published by our group [4–6], are associated
with the other two targets unveiled in the present
combined analysis of proteomics and oligonucleotide
expression arrays: HSPB1/HSP27 and nucleolin (NCL)
demonstrated in Fig. 6. HSPB1/HSP27 is downstream of
the canonical activation of EGFR through the transcrip-
tion factor, nuclear estrogen receptor 1 (ESR1) [31].
Nucleolin (NCL) is a nucleolar phosphoprotein involved
in the synthesis and maturation of ribosomes, found asso-
ciated with intranuclear chromatin and pre-ribosomal
particles, which induces chromatin decondensation by
binding to histone H1. NCL plays a role in pre-rRNA
transcription and ribosome assembly in the process of
transcriptional elongation. NCL is downstream to RKIP in
a canonical pathway, where RKIP down-regulates BRAF
as demonstrated in melanoma cancer cells [32]. BRAF
negatively regulates AKT [33] through directly binding to
Rictor (mTORC2) [34]. AKT phosphorylates MYT1
kinase and decreases its activity [35], and the latter
Fig. 6 MetaCore analysis of differential modulated proteins in glioma tumors. The NPM1, RKIP, GRP78, HSP27 (HSPB1) and NCL proteins were
subjected to network interactions using the MetaCore software and placed in a context of systems biology implying important findings to contribute
to the progress of studies in glioma tumorigenesis and their participation in canonical pathways. See MetaCore symbol legend in Additional file 2:
Figure S2
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[36]. CDK1 maintains NCL stability via phosphoryl-
ation during mitosis [37]. We have previously demon-
strated that RKIP was down-regulated in gliomas [4],
and therefore, RKIP would also determine down-
regulation of NCL through this pathway. In contrast,
NPM1 which is up-regulated in glioma [4] physically
interacts with NCL and increases its activity [38]. On
the other hand, HSPB1/HSP27 also up-regulates NCL,
by binding to STAT3 [39], and ultimately, STAT3 may
bind to NCL promoter [40], leading to cell prolifera-
tion. HSPB1/HSP27 may also activate NCL through
SP1 [41], as NCL has been reported to physically
interact with SP1 in non-small cell lung cancer [42],
and human epidermal keratinocytes [43]. This NCL ac-
tivation by HSPB1/HSP27 may receive reinforcement
through GRP78, which physically interacts with ESR1 in-
creasing its activity [44], which in turn also activates
HSPB1/HSP27 promoter [45]. Therefore, HSPB1, GRP78
and EGFR may be linked through activation of two tran-
scription factors, ESR1 and STAT3, and through a third
transcription factor, SP1, this loop may be linked to RKIP,
NCL and NPM1.The present findings of HSPB1 expression enhance-
ment with the tumor malignant progression, and NCL
high expression in astrocytomas are in accordance with
previously demonstrated differential expression of
GRP78, NPM1 [4, 6] and EGFR [46] according to the
malignant grade of astrocytomas, corroborating the rele-
vance of this network in the progression of
astrocytomas.
The combined methodology applied herein not only
confirmed the relevance and the involvement of the
molecular triad, NPM1, GRP78 and RKIP with glioma
malignancy, but additionally has uncovered two new
important targets: NOVA1, useful for the diagnostic
refinement between astocytoma and oligodendroglioma,
and HSPB1, as a predictive factor of poor prognosis for
glioblastoma.Conclusions
Taken together, our quantitative proteomic analysis
detected the molecular triad, NPM1, GRP78 and RKIP
participating together with NCL and HSP27/HSPB1 in a
network related to tumor progression. Additionally, two
Gimenez et al. BMC Cancer  (2015) 15:481 Page 12 of 13new important targets were uncovered: NOVA1 useful
for diagnostic refinement differentiating astrocytoma
from oligodendroglioma, and HSPB1/HSP27, as a pre-
dictive factor of poor prognosis for GBM.
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